RLS-2201 Manufacturing and Regulatory Pathway Initiated
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The company has begun engineering batch manufacturing at BioCina and engaged a US regulatory advisor to prepare for an FDA submission. These developments are crucial for the company as it aims to start clinical trials in the latter half of the upcoming year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Patrys
- Appendix 4D - Half Year Accounts - 31 December 2025
- Appointment of Chief Executive Officer
- Appendix 4C - Quarterly - 31 December 2025
- Investor Presentation
- Completion of Acquisition and Board Appointments
Later from Patrys
- Investor Presentation - Broker Meets Biotech
- $3.2 million Placement to Advance Clinical Trials
- Appendix 4C - Quarterly - 31 March 2026
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Patrys Secures 50% Revenue Share in IP Commercialisation
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys